Clinical trials: in Austria
Metastatic Non-small Cell Lung Cancer
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients…
- Trial name
- LUNAR-2 (NCT06216301)
- Testing
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
- Where
- 104 sites in United States, Austria and 15 more
- Volunteers
- 734 people
- Sponsor
- NovoCure GmbH
Advanced Melanoma
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
- Trial name
- NCT06697301
- Testing
- EIK1001, Pembrolizumab (KEYTRUDA® )
- Where
- 127 sites in United States, Australia and 22 more
- Volunteers
- 740 people
- Sponsor
- Eikon Therapeutics
Preterm Neonate, Temperature Monitoring
Continuous Monitoring of Body Temperature in Mothers and Their Preterm Neonates
Preterm babies are at increased risk of becoming too cold or too warm immediately after birth because they have an immature ability to regulate their body temperature.
- Trial name
- MonT NeoP (NCT07758205)
- Testing
- Temperature monitoring
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Graz
Therapeutic Hypothermia, Neonatal Hypoxic-Ischemic Encephalopathy
Continuous Monitoring of Body Temperature in Neonates During Therapeutic Hypothermia
This prospective observational pilot study aims to evaluate the feasibility, accuracy, and safety of the SteadyTemp® wireless adhesive thermometer for continuous, non-invasive body temperature monitoring in neonates undergoing…
- Conditions
- Therapeutic Hypothermia, Neonatal Hypoxic-Ischemic Encephalopathy, Neonatal Thermal Management
- Trial name
- MonT HT (NCT07756892)
- Testing
- continous temperature measurement
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Graz
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with…
- Trial name
- ENDURA-2 (NCT06961214)
- Testing
- Depemokimab
- Where
- 193 sites in United States, Argentina and 14 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline
ACL - Anterior Cruciate Ligament Rupture
SharkScrew ACL RCT
This prospective, randomized controlled trial will compare three tibial interference screw types used for graft fixation during primary anterior cruciate ligament (ACL) reconstruction: a polyetheretherketone (PEEK) screw, a…
- Trial name
- NCT07830953
- Testing
- ACL Reconstruction with a Biocomposite Screw, ACL Reconstruction using a PEEK Screw, ACL Reconstruction using an Allograft Screw
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Austrian Workers Compensation Board Styria
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV
PPH - Postpartum Hemorrhage, Eclampsia
Comparing Simulated Patients and Manikin Based Simulation in Obstetrics
The aim of this randomized study is to compare a live, trained simulated patient with a high-fidelity manikin in obstetric emergency team training using two standardized scenarios.
- Trial name
- NCT07857551
- Testing
- Trained, standardized patient, MamaAnne Patient Simulator
- Where
- Austria
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Glioblastoma Multiforme
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone.
- Trial name
- EF-32 (NCT04471844)
- Testing
- Optune®
- Where
- 130 sites in United States, Austria and 9 more
- Volunteers
- 981 people
- Sponsor
- NovoCure Ltd.
Intensive Care Patients, Intensive Care Unit Patients
The Intensive Care Platform Trial
Among critically ill patients, many die, and many of the survivors and their family members struggle for years with reduced quality of life. Critically ill patients are treated in intensive care units (ICUs).
- Conditions
- Intensive Care Patients, Intensive Care Unit Patients, Critical Illness
- Trial name
- INCEPT (NCT06667999)
- Testing
- Albumin, No albumin use, LMWH in weight-adjusted dose
- Where
- 40 sites in Austria, Denmark and 5 more
- Volunteers
- 10,000 people
- Sponsor
- Anders Perner
Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab…
- Trial name
- NCT07155187
- Testing
- Telisotuzumab Adizutecan, Standard of Care, Osimertinib
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 490 people
- Sponsor
- AbbVie
Handwriting, Graphomotor Impairment
Evaluation of Grip'n'Play
The goal of this study is to evaluate Grip'n'Play, a set of tablet games controlled with the SensoGrip pen, which provides visual feedback on grip and writing pressure.
- Trial name
- NCT07846449
- Testing
- Grip'n'Play, Workbook
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Hochschule Campus Wien (University of Applied Sciences Campus Vienna)
Rheumatic Disorder, Rheumatoid Arthritis (RA)
DETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response
The goal of this clinical trial is to learn if the DETECTRA remote monitoring platform can help clinicians detect rheumatoid arthritis (RA) disease flares earlier and more reliably, as well as identify response and non-response…
- Trial name
- Pix-Monitor (NCT07857993)
- Testing
- DETECTRA, Standard of Care (SOC)
- Where
- 3 sites in Austria, Germany
- Volunteers
- 320 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT03007147
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 352 people
- Sponsor
- Children's Oncology Group
Thrombotic Thrombocytopenic Purpura (TTP)
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare blood disorder that some people are born with. It is caused by a problem in a gene passed down from parents to children, which affects the body's ability to produce…
- Trial name
- NCT07353099
- Testing
- No Intervention
- Where
- 7 sites in Austria, Germany
- Volunteers
- 50 people
- Sponsor
- Takeda
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 303 (NCT07491445)
- Testing
- daraxonrasib, gemcitabine, nab-paclitaxel
- Where
- 82 sites in United States, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- Revolution Medicines, Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in…
- Trial name
- NCT06680817
- Testing
- Faricimab
- Where
- 59 sites in Austria, Bulgaria and 13 more
- Volunteers
- 875 people
- Sponsor
- Hoffmann-La Roche
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active…
- Trial name
- Ametrine-2 (NCT06588855)
- Testing
- Afimkibart
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 350 people
- Sponsor
- Hoffmann-La Roche
Immunoglobulin A Nephropathy, IgAN
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
- Trial name
- I CAN (NCT06291376)
- Testing
- Ravulizumab
- Where
- 246 sites in United States, Argentina and 26 more
- Volunteers
- 584 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Friedreich Ataxia
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older.
- Trial name
- BRAVE (NCT06953583)
- Testing
- Omaveloxolone
- Where
- 34 sites in United States, Australia and 14 more
- Volunteers
- 255 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.